Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jul 18, 2016 (10 years ago)

Bactroban Nasal

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Penicillin Cross Contamination

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

Bactroban Nasal, (Mupirocin Calcium Ointment 2%), 1 gram Single Use Tubes, Rx only, GlaxoSmithKline, Research Triangle Park, NC 27709, NDC 0029-1526-11.

Affected NDC 0029-1526-11

Compare with the code on your package — it is the most precise check available.

Drug: Mupirocin

Recalling firm
GlaxoSmithKline, LLC
NDC code
0029-1526-11
Origin
NC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1444-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Mupirocin recalls

See all
Class II · Moderate risk

Mupirocin Ointment

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 0093-1010-42 D-1075-2022

Other recalls by GlaxoSmithKline, LLC

All 2016 recalls
Class III · Low risk

Tivicay PD

Labeling: Incorrect Lot and/or Expiration Date: The carton has incorrect expiration of 2026-MAY*, whereas the correct expiration date, which is on the tablet bottle label, is 2025-APR.

Terminated Labeling / mix-up GlaxoSmithKline LLC NDC 49702-255-37 D-0544-2024
Class III · Low risk

Anoro Ellipta

Failed Release Testing: Coarse Particle Mass for umeclidinium Out of Specification

Terminated Failed specification GlaxoSmithKline LLC NDC 0173-0869-10 D-0160-2024
Class III · Low risk

Tivicay (dolutegravir)

Labeling: incorrect or missing lot and/or expiration date. An incorrect expiration date was printed on the product labeling with an expiration date of January 2027, whereas the correct expiration date is September 2026.

Terminated Labeling / mix-up GlaxoSmithKline LLC NDC 49702-228-13 D-0896-2022
Class II · Moderate risk

Ventolin HFA

Defective Delivery System: Elevated number of units with out of specification results for leak rate

Ongoing Packaging defect GlaxoSmithKline, LLC NDC 0173-0682-20 D-0793-2017